framycetin has been researched along with Myocardial Infarction in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (75.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| BEST, MM; DUNCAN, CH | 1 |
| Bauer, B; Kloner, RA; Przyklenk, K; Simkhovich, BZ | 1 |
| Markkanen, T; Salmi, HA; Sotaniemi, E | 1 |
1 trial(s) available for framycetin and Myocardial Infarction
| Article | Year |
|---|---|
Effect of neomycin treatment on the vitamin B12 content of human serum and urine.
Topics: Blood; Clinical Trials as Topic; Humans; Myocardial Infarction; Neomycin; Urine; Vitamin B 12 | 1965 |
3 other study(ies) available for framycetin and Myocardial Infarction
| Article | Year |
|---|---|
EFFECTS OF CHOLESTEROL-LOWERING DRUGS ON SERUM TRIGLYCERIDES.
Topics: Androsterone; Angina Pectoris; Arteriosclerosis; Cholesterol; Diabetes Mellitus; Humans; Lipids; Myocardial Infarction; Neomycin; Sterols; Thyroxine; Triglycerides | 1964 |
Preconditioning-induced cardioprotection and release of the second messenger inositol (1,4,5)-trisphosphate are both abolished by neomycin in rabbit heart.
Topics: Animals; Heart; Hemodynamics; In Vitro Techniques; Inositol 1,4,5-Trisphosphate; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardium; Neomycin; Protein Synthesis Inhibitors; Rabbits; Second Messenger Systems | 1999 |
Lipid-lowering drugs.
Topics: Cellulose; Cholestyramine Resin; Clofibrate; Drug Evaluation; Humans; Hyperlipidemias; Lipids; Myocardial Infarction; Neomycin; Nicotinic Acids | 1975 |